We are live on ! Find out more
OPXAW

Opexa Therapeutics, Inc.
OPXAW

Delisted

OPXAW was delisted on the 20th of September, 2017.

Back to rankings

5 hedge funds and large institutions have $137K invested in Opexa Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more funds holding

Funds holding: 4 → 5 (+1)

27% less capital invested

Capital invested by funds: $188K → $137K (-$51K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.13%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$2.42K

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$466
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$112K – – –
California Public Employees Retirement System
2
California Public Employees Retirement System
California
$19K – – –
EEG
3
E.E. Geduld
$4K – – –
SM
4
Sabby Management
Florida
$2K +$2.42K +34,097 New
UBS Group
5
UBS Group
Switzerland
– -$466 -6,575 -62%

OPXAW Hedge Fund Activity: Q1 2016 in Review

5 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Opexa Therapeutics, Inc. (OPXAW) for Q1 2016, worth a combined $137K — down 27% from $188K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new OPXAW positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.42K. The largest seller was UBS Group, cutting an estimated $466.

  • 5 institutional investors held Opexa Therapeutics, Inc. (OPXAW) as of Q1 2016, up from 4 in Q4 2015.
  • Funds reported $137K of Opexa Therapeutics, Inc. stock for Q1 2016, down 27% quarter-over-quarter.
  • 1 fund opened new Opexa Therapeutics, Inc. positions in Q1 2016 and 0 closed out, a net change of +1 holder.
  • The largest Opexa Therapeutics, Inc. buyer in Q1 2016 was Sabby Management, an estimated $2.42K added.
  • The largest Opexa Therapeutics, Inc. seller in Q1 2016 was UBS Group, an estimated $466 sold.

Based on aggregated 13F filings for Q1 2016.